Please ensure Javascript is enabled for purposes of website accessibility
Maxx Chatsko

Maxx Chatsko


Maxx has been a contributor to since 2013. He graduated from the State University of New York College of Environmental Science and Forestry (2012) with a Bachelor of Science in Bioprocess Engineering and from Carnegie Mellon University (2016) with a Master of Science in Materials Science & Engineering.

Recent articles

paper airplanes rising

Here's Why Repligen Rose 33.6% in the First Half of 2020

Investors have come to value the company's resilience in an uncertain year.

scientist dejected

Here's Why Guardant Health Dropped 10.2% in June

A public offering of common stock pushed the stock lower, but strengthened the company's balance sheet.

295 cargo ship

Here's Why Bloom Energy Rose 35.5% in June

Most of the monthly gains were driven by progress in an important collaboration.

blocks arrows rising

Here's Why Arrowhead Pharmaceuticals Stock Jumped 34% in June

The RNAi treatment developer is clawing its way back after a rough start to 2020.

dude pointing up

Here's Why BioNTech Gained 34.8% in June

One of the world's leading coronavirus vaccine efforts reported promising progress.

600 scientist microscope

Here's Why Mesoblast Stock Rose Over 18% Today

The Australian biopharma earned an important clearance to treat COVID-19 patients in the United States, which could be a sign of things to come.

352 nat gas pipe construction

Dominion Energy Stock Falls 11.3% After the Atlantic Coast Pipeline Is Axed

The energy giant also agreed to divest its natural gas transmission and storage assets to Berkshire Hathaway. The proceeds will not be used to fund the company's ambitious renewable energy portfolio.

chalkboard stock down pink

Here's Why Neoleukin Therapeutics Dropped Today

The development-stage drug company announced the pricing of a public offering of common stock.

534 eye drops

Is Aerie Pharmaceuticals a Buy?

Wall Street has given the eye-care specialist the cold shoulder in 2020. Is that an opportunity for individual investors?

046 dna model

Is Iovance Biotherapeutics a Buy?

After rumors swirled about a potential acquisition, it now appears the biopharma is transitioning to commercial operations as a standalone company.

arrow up shelves

Here's Why BioNTech Jumped Today

The German biopharma announced a $250 million private investment.

paper airplanes rising

Here's Why Athersys Stock Is Soaring Today

The stem cell stock jumped after a major Wall Street firm initiated coverage, but there's a catch.

297 head in sand

Is Wall Street Wrong About Mesoblast?

The cell therapy developer expects to have clinical data for its COVID-19 treatment soon. Will it deliver a historic success or continue the poor track record of stem cell candidates?

236 worried investor

Shares of Renewable Energy Group Slide After Revising Q2 Outlook Lower

The biomass-based diesel leader is suffering from both poor market conditions and embarrassing errors in its previous guidance.

multiple lines up

Here's Why Agenus Stock Jumped Higher Today

The development-stage biopharma delivered two encouraging updates.

coins in hands stock up

Silver Stocks Jump as Confirmed COVID-19 Cases Rise

Investors are betting precious metals will prove resilient through the ongoing economic slowdown.

dude tossing stacks

Invitae Surges on $1.4B Acquisition of ArcherDX

The genetic testing company pulled the trigger on its largest acquisition yet.

funky arrows rising

Here's Why Selecta Biosciences Stock Is Soaring Today

A bullish article is sending shares higher.

multiple lines down

Here's Why IDEAYA Biosciences Lost Nearly 23% Today

The development-stage drug developer is selling common stock to raise cash. It's a wise move.

076 arrow dude getty

Here's Why PolyMet Mining Is Soaring This Week

The development-stage mining company is one step closer to starting operations at a long-delayed project in Minnesota.